Richard J Robb

US Patent:

20010012517, Aug 9, 2001

Filed:

Mar 26, 2001

Appl. No.:

09/816266

Inventors:

Mircea Popescu - Plainsboro NJ, US
Lawrence Boni - Monmouth Junction NJ, US
Richard Robb - Princeton Junction NJ, US
Michael Batenjany - Hamilton NJ, US

International Classification:

A61K039/00
A61K009/127

US Classification:

424/277100, 424/450000

Abstract:

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

US Patent:

20020051813, May 2, 2002

Filed:

Jun 1, 2001

Appl. No.:

09/870691

Inventors:

Lawrence Boni - Monmouth Junction NJ, US
Michael Batenjany - Hamilton NJ, US
Richard Robb - Princeton Junction NJ, US
Mircea Popescu - Plansboro NJ, US
Mary Neville - Jamesburg NJ, US

International Classification:

A61K009/127
A61K038/19
A61K038/20
A61K031/739

US Classification:

424/450000, 424/085100, 424/085200, 514/054000

Abstract:

The invention describes a Lipomatrix composed of lipid lattices of stacked bilayers which, when hydrated, form liposomes. The invention also provides a simplified method used to generate highly effective liposomal preparations. Vaccine compositions having superior immunological properties use biomedical-grade liposomes which can be produced from a Lipomatrix, using safe and efficient methods. Use of the inventive methods produces highly potent vaccines against tumor antigens.

US Patent:

20020155135, Oct 24, 2002

Filed:

Apr 12, 2002

Appl. No.:

10/120450

Inventors:

Mircea Popescu - Plansboro NJ, US
Lawrence Boni - Monmouth Junction NJ, US
Richard Robb - Princeton Junction NJ, US
Michael Batenjany - Hamilton NJ, US

Assignee:

BIOMIRA U.S.A., Inc.

International Classification:

A61K039/00
C12N005/08

US Classification:

424/277100, 435/372000

Abstract:

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

US Patent:

6207170, Mar 27, 2001

Filed:

Jan 15, 1999

Appl. No.:

9/231650

Inventors:

Mircea C. Popescu - Plansboro NJ
Lawrence Boni - Monmouth Junction NJ
Richard J. Robb - Princeton Junction NJ
Michael M. Batenjany - Hamilton NJ

Assignee:

Biomira U.S.A., Inc. - Cranbury NJ

International Classification:

A61K39/00;39/385;39/39;47/00;47/02

US Classification:

4242771

Abstract:

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

US Patent:

56587449, Aug 19, 1997

Filed:

Jul 22, 1994

Appl. No.:

8/277299

Inventors:

Augusto C. Ochoa - Frederick MD
Howard A. Young - Gaithersburg MD
Dan L. Longo - Kensington MD
Paritosh Ghosh - Frederick MD
Richard Robb - Princeton Junction NJ
Mary Neville - Jamesburg NJ

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Biomira USA Inc. - Cranbury NJ

International Classification:

C12Q 168
G01N 3368

US Classification:

435 724

Abstract:

Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM). In addition, the ratio of a TH-1-type BRM to a TH-2-type BRM, the ratio of cytoplasmic to nuclear levels of polynucleotide binding proteins, the pattern of protein binding to an oligonucleotide probe that comprises the protein binding region of a gene for a BRM, or the pattern of distribution of T lymphocytes in a density gradient following density gradient centrifugation are also suitable as an immune status index. The methods are useful in identifying patients exhibiting immunosuppression, hyperimmunity and autoimmunity, as well as in assessing the immune status of a patient undergoing organ transplant.

US Patent:

20200376101, Dec 3, 2020

Filed:

May 22, 2020

Appl. No.:

16/881580

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
C12Q 1/6886

Abstract:

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.

US Patent:

20200054726, Feb 20, 2020

Filed:

Oct 9, 2019

Appl. No.:

16/597582

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
A61K 9/00
A61K 45/06
A61K 9/127

Abstract:

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.

US Patent:

20170224796, Aug 10, 2017

Filed:

Feb 3, 2017

Appl. No.:

15/424473

Inventors:

- Lombard IL, US
Richard J. Robb - Gaithersburg MD, US

International Classification:

A61K 39/00
C12Q 1/68

Abstract:

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule.